What is the catalog number for BMS-1?

The catalog number for BMS-1 is HY-19991.

What sizes are available for BMS-1?

BMS-1 is available in the following size(s): 5 mg, 10 mM - 1 mL, 10 mg, 25 mg, 50 mg, 100 mg.

How many pack sizes does BMS-1 come in?

BMS-1 is available in 6 different pack sizes.

BMS-1 is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures BMS-1?

BMS-1 is manufactured by QuantiMol.

What is the estimated delivery time for BMS-1?

Estimated delivery time for BMS-1 is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for BMS-1?

The safety data sheet for BMS-1 is available here: http://file.medchemexpress.com/batch_PDF/HY-19991/BMS-1-SDS-MedChemExpress.pdf.

BMS-1

BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM) [1][2].

Product Specifications

CAS Number

1675201-83-8

Product Name Alternative

PD-1/PD-L1 inhibitor 1

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; PD-1/PD-L1

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/PD1-PDL1-inhibitor-1.html

Concentration

10mM

Purity

99.71

Solubility

DMF : 5 mg/mL (ultrasonic) |DMSO : 7.14 mg/mL (ultrasonic) |Methanol : 25 mg/mL (ultrasonic)

Smiles

O=C([C@H]1N(CC2=C(OC)C=C(OCC3=C(C)C(C4=CC=CC=C4)=CC=C3)C=C2OC)CCCC1)O

Molecular Formula

C29H33NO5

Molecular Weight

475.58

Precautions

H302, H315, H319, H335

References & Citations

[1]Zhao Y, et al. Depression Promotes Hepatocellular Carcinoma Progression through a Glucocorticoids Mediated Up-Regulation of PD-1 Expression in Tumor infiltrating NK Cells. Carcinogenesis. 2019 Feb 4.|[2]Li K, et al. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy. J Drug Target. 2019 Mar;27 (3) :244-256.|[3]Zhang H, et al. Utilizing VEGF165b mutant as an effective immunization adjunct to augment antitumor immune response. Vaccine. 2019 Apr 3;37 (15) :2090-2098.|[4]Mengyuan Li, et al. KALRN mutations promote antitumor immunity and immunotherapy response in cancer. J Immunother Cancer. 2020 Oct;8 (2) :e000293.